01
Cash & equivalents increased 62.4%
Cash & equivalents changed +62.4% from the comparable as-filed period.
$58.3M→$94.7MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTImageneBio, Inc.'s latest supported as-filed period reports revenue of $800,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +62.4% from the comparable as-filed period.
Net income changed -267.8% from the comparable as-filed period.
Operating income changed -34.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
IMA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001803794-26-000003SEC ↗4Aug 17, 2026Period Aug 14, 20260002064348-26-000003SEC ↗10-QAug 5, 2026Period Jun 30, 20260001193125-26-333920SEC ↗8-KAug 5, 2026Period Aug 5, 20260001193125-26-333912SEC ↗4Jul 28, 2026Period Jul 25, 20260001803794-26-000002SEC ↗8-KJul 23, 2026Period Jul 20, 20260001193125-26-314167SEC ↗4Jul 20, 2026Period Jul 16, 20260002126940-26-000004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026Filed Aug 17, 2026 | Yarema KristinChief Executive Officer | Grant Or AwardDirect | 254,800 | $0 | $0 | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Yarema KristinChief Executive Officer | Grant Or AwardDirect | 137,200 | $0 | $0 | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Yarema KristinChief Executive Officer | Grant Or AwardDirect | 250,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +65.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +98.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-285424